N4 Pharma PLC Patent filing update (8091E)
01 Novembre 2022 - 8:00AM
UK Regulatory
TIDMN4P
RNS Number : 8091E
N4 Pharma PLC
01 November 2022
01 November 2022
N4 Pharma Plc
("N4 Pharma" or the "Company")
Patent filing update
N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company
developing Nuvec(R), a novel delivery system for cancer treatments
and vaccines, provides an update on its patent application for
Nuvec(R), filed in March 2020 (no. PCT/GB2021/050960 Gene Therapy
Vectors).
The Company originally filed a Patent Cooperation Treaty ("PCT")
patent application for Nuvec(R) to be used to manufacture viral
vectors and to make viral vectors more efficient in applications
such as ex-vivo gene therapy treatments. Under the terms of the PCT
application process and following feedback from an international
patent search, the Company is now making enhancements to the claims
of the applications in the territories in which it wishes to gain
patent protection. N4 pharma is pursuing this patent application
which, if granted, would be in addition to the patents it has
exclusively licensed from the University of Queensland.
The Company has decided to focus its claims on the use of the
specific spiky properties of Nuvec(TM) to load and transfect viral
vectors, especially adenoviral vectors and lentiviral vectors. This
is based on feedback from the examiner and further work the Company
has done that has shown how combining Nuvec(R) with adenoviral
vectors (in addition to its earlier work on lentiviral vectors) can
lead to an improvement in vector performance and a reduction in the
amount of the viral vector needed.
The Company has filed ongoing patent applications in the
following territories: Europe (including UK); USA; Japan; India and
Canada. It will also file applications in Australia and China in
due course.
Nigel Theobald, Chief Executive Officer of the Company,
commented:
"We are seeking to refine our claims to give this patent the
greatest chance of being granted in a field with strong commercial
opportunity. Should the patent be granted in these territories it
would mirror the regions granted for the main patent which the
Company has licensed from the University of Queensland and further
strengthen the commercial protection of Nuvec (R) ."
Enquiries:
N4 Pharma Plc Via IFC Advisory
Nigel Theobald, CEO
Luke Cairns, Executive Director
SP Angel Corporate Finance LLP Tel: +44 (0)20
Nominated Adviser and Joint Broker 3470 0470
Matthew Johnson/Caroline Rowe (Corporate
Finance)
Vadim Alexandre/Rob Rees (Corporate
Broking)
IFC Advisory Limited Tel: +44 (0)20
Financial PR 3934 6630
Graham Herring
Zach Cohen
About N4 Pharma
N4 Pharma is a specialist pharmaceutical company developing a
novel delivery system for cancer and vaccine treatments using its
unique silica nanoparticle delivery system called Nuvec(R).
N4 Pharma's business model is to partner with companies
developing novel antigens for cancer and vaccine treatments to use
Nuvec(R) as the delivery vehicle to get their antigen into cells to
express the protein needed for the required immunity. As these
products progress through pre clinical and clinical programs, N4
Pharma will seek to receive up front payments, milestone payments
and ultimately royalty payments once products reach the market.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCFDDFWFEESEIS
(END) Dow Jones Newswires
November 01, 2022 03:00 ET (07:00 GMT)
N4 Pharma (AQSE:N4P.GB)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024
N4 Pharma (AQSE:N4P.GB)
Graphique Historique de l'Action
De Déc 2023 à Déc 2024